#POLB Poolbeg Pharma PLC – POLB 001 LPS Challenge Trial Paper Published January 28, 2026 – Posted in: Poolbeg Pharma (POLB)

28 January 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Key conclusions from the paper include: · POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers · POLB 001 was safe and well tolerated across…

#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of…

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Pneumagen, a clinical-stage biotech company, reporting successful clinical proof of concept for its broad-spectrum antiviral candidate Neumifil, demonstrated from a Phase 2a influenza human challenge study conducted by hVIVO. The randomised, double-blind, placebo-controlled study enrolled 104 healthy adult volunteers, recruited through the FluCamp platform, and evaluated two dose regimens…

#POLB Poolbeg Pharma PLC – POLB 001 LPS Challenge Trial Paper Published January 28, 2026 – Posted in: Poolbeg Pharma (POLB)

#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

Address

Contact

Social

LEGAL